Protalix BioTherapeutics to Present at Annual Global Conference
Protalix BioTherapeutics, Inc. (NYSE American: PLX) is a biopharmaceutical company recognized for its dedication to developing and producing innovative therapeutic proteins. The company is gearing up to present at a significant investment conference, with Dror Bashan, the President and CEO of Protalix, representing the organization during the H.C. Wainwright 26th Annual Global Investment Conference.
Conference Details and Engagements
This important event is set to take place from September 9 to 11, bringing together industry leaders to discuss advancements in the sector and explore potential investment opportunities.
Mr. Bashan will deliver his presentation on September 11 at 12:30 p.m., where he will share insights into Protalix's innovative strategies and product pipeline. Additionally, company management will engage in one-on-one meetings with registered investors throughout the conference, facilitating in-depth discussions about their projects and financial outlook.
About Protalix BioTherapeutics, Inc.
Protalix distinguishes itself in the biopharmaceutical sector through its unique method of producing therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. This groundbreaking approach has enabled Protalix to become the first company to receive FDA approval for a protein produced via plant cell technology. A significant milestone for the company was the licensing of taliglucerase alfa, which is aimed at treating Gaucher disease, to Pfizer Inc.
Innovative Products in Development
Elfabrio, Protalix’s newest product, achieved dual approvals from both the FDA and EMA in May 2023, marking a pivotal moment for the company. Additionally, Protalix has formed a partnership with Chiesi Farmaceutici S.p.A. to expand the global reach and effectiveness of Elfabrio.
Pipeline and Future Aspirations
The company’s development pipeline features a variety of proprietary recombinant therapeutic proteins that address critical needs in the pharmaceutical market. This includes PRX–115, a PEGylated uricase aimed at managing uncontrolled gout, and PRX–119, which targets NETs-related diseases with a long-acting DNase I formulation.
Investor Relations
For inquiries, investors can reach out to Mike Moyer, Managing Director at LifeSci Advisors, by calling +1-617-308-4306. Protalix is committed to maintaining transparency and regularly updates stakeholders on its developments.
Frequently Asked Questions
What is Protalix BioTherapeutics known for?
Protalix BioTherapeutics specializes in developing and commercializing recombinant therapeutic proteins using its ProCellEx plant cell-based expression system.
Who will present at the investment conference?
Dror Bashan, the President and CEO of Protalix, is scheduled to present at the conference.
When is the conference being held?
The H.C. Wainwright 26th Annual Global Investment Conference will take place from September 9 to 11.
What recent product approvals has Protalix achieved?
Elfabrio has recently received approvals from both the FDA and EMA, highlighting Protalix’s expanding presence in the biopharmaceutical market.
How can investors contact Protalix for more information?
Investors can reach Mike Moyer at LifeSci Advisors by calling +1-617-308-4306 for inquiries and additional information.
